Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach

The recent failures of cholesteryl ester transport protein inhibitor drugs to decrease CVD risk, despite raising HDL cholesterol (HDL-C) levels, suggest that pharmacologic increases in HDL-C may not always reflect elevations in reverse cholesterol transport (RCT), the process by which HDL is believe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadkar, Kapil, Lu, James, Sahasranaman, Srikumar, Davis, John, Mazer, Norman A., Ramanujan, Saroja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Biochemistry and Molecular Biology 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689335/
https://www.ncbi.nlm.nih.gov/pubmed/26522778
http://dx.doi.org/10.1194/jlr.M057943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689335/
https://www.ncbi.nlm.nih.gov/pubmed/26522778
http://dx.doi.org/10.1194/jlr.M057943

Ejemplares similares